Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC

Summary

The purpose of this study is to compare the Overall Survival (OS) of HCC patients who receive brivanib as adjuvant treatments to TACE therapy, with the OS of HCC patients who receive matched placebo with TACE therapy.

Timeline

Start

2009-07-20

Primary completion

2012-09-28

Completion

2018-01-26

Drugs

Indications